Bronchiectasis Market

Market Overview:

The 7 major bronchiectasis markets reached a value of US$ 438.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 731.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034.

The bronchiectasis market has been comprehensively analyzed in IMARC's new report titled "Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchiectasis refers to a chronic respiratory disorder characterized by the permanent enlargement and damage of the airways in the lungs. In this condition, the bronchi (the larger airways in the lungs) become widened, thickened, and less elastic, leading to the accumulation of mucus and impaired clearance of bacteria and other irritants from the airways. Some of the common symptoms associated with the ailment include chronic cough, which often produces large amounts of thick mucus, recurrent respiratory infections, wheezing, shortness of breath, fatigue, chest discomfort or pain, etc. The diagnosis of bronchiectasis typically involves a combination of medical history evaluation, physical examination, imaging tests, and lung function assessments. The doctor will inquire about disease symptoms, previous respiratory infections, and any underlying conditions. Various imaging procedures, such as high-resolution computed tomography (HRCT) scan, provide detailed images of the airways, enabling the identification of bronchiectasis and its extent. Several lung function tests, including spirometry and lung volume measurements, help to assess lung function and determine any associated respiratory impairments. In some instances, genetic testing may be performed to investigate underlying genetic causes, particularly in suspected cases of cystic fibrosis-related bronchiectasis.

The rising cases of repeated or severe respiratory infections, such as pneumonia, whooping cough, tuberculosis, etc., which cause inflammation and damage to the airway walls, are primarily driving the bronchiectasis market. In addition to this, the increasing prevalence of certain autoimmune conditions like rheumatoid arthritis, cystic fibrosis, immunodeficiency disorders, etc., that increase the risk of bronchiectasis, is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous mucolytic medications, such as mannitol and hypertonic saline, since they can help in thinning the mucus, thereby rendering it easier to clear from the airways, is further augmenting the market growth. Additionally, several key players are making extensive investments in R&D activities to investigate the potential of various biologics, including monoclonal antibodies, in reducing airway inflammation and preventing exacerbations. This, in turn, is also acting as another significant growth-inducing factor. Furthermore, the escalating demand for oscillatory positive expiratory pressure devices (OPEP), which are handheld devices that help to create vibrations in the airways during exhalation and facilitate mucus clearance, is expected to drive the bronchiectasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bronchiectasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiectasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchiectasis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bronchiectasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bronchiectasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bronchiectasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bronchiectasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bronchiectasis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bronchiectasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bronchiectasis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bronchiectasis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bronchiectasis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with bronchiectasis across the seven major markets?
• What is the size of the bronchiectasis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bronchiectasis?
• What will be the growth rate of patients across the seven major markets?
   

Bronchiectasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bronchiectasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiectasis market?
• What are the key regulatory events related to the bronchiectasis market?
• What is the structure of clinical trial landscape by status related to the bronchiectasis market?
• What is the structure of clinical trial landscape by phase related to the bronchiectasis market?
• What is the structure of clinical trial landscape by route of administration related to the bronchiectasis market?